A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia.

Trial Profile

A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2018

At a glance

  • Drugs Alemtuzumab (Primary) ; Ofatumumab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Feb 2018 Planned End Date changed from 1 May 2018 to 1 May 2020.
    • 14 Feb 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top